| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1166272M |
| P356 | DOI | 10.1371/JOURNAL.PONE.0166272 |
| P932 | PMC publication ID | 5102450 |
| P698 | PubMed publication ID | 27829066 |
| P50 | author | Victoria Cachofeiro | Q42731331 |
| Ernesto Martinez-Martinez | Q42364398 | ||
| P2093 | author name string | Patrick Rossignol | |
| Jaime Ibarrola | |||
| Laurent Calvier | |||
| Natalia Lopez-Andres | |||
| Celine Leroy | |||
| Amaya Fernandez-Celis | |||
| P2860 | cites work | Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition | Q43096173 |
| Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. | Q43786750 | ||
| Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis | Q44579295 | ||
| A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury | Q46461255 | ||
| Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes | Q80477531 | ||
| Mechanisms of tubulointerstitial fibrosis | Q85074102 | ||
| Reversibility of chronic kidney disease and outcomes following aortic valve replacement† | Q85607054 | ||
| Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3 | Q24624887 | ||
| Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis | Q24649584 | ||
| The Role of Galectin-3 in the Kidneys | Q26752754 | ||
| Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model | Q28142724 | ||
| Up-regulation of galectin-3 in acute renal failure of the rat | Q28344724 | ||
| Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease | Q28534290 | ||
| Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement | Q33383245 | ||
| Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury | Q33873592 | ||
| The role of tubulointerstitial injury in chronic renal failure. | Q33886665 | ||
| Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis | Q34501897 | ||
| Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. | Q35109460 | ||
| Risk factors for progressive chronic kidney disease | Q35159360 | ||
| New insights into epithelial-mesenchymal transition in kidney fibrosis | Q36010095 | ||
| Renal fibroblasts and myofibroblasts in chronic kidney disease | Q36621203 | ||
| How does proteinuria cause progressive renal damage? | Q36621209 | ||
| Elevated galectin-3 precedes the development of CKD | Q37119904 | ||
| Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model | Q37423079 | ||
| Prediction, progression, and outcomes of chronic kidney disease in older adults | Q37496352 | ||
| Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. | Q37873557 | ||
| Galectin-3 inhibition prevents adipose tissue remodelling in obesity. | Q38382993 | ||
| Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension | Q38387964 | ||
| Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity. | Q40560953 | ||
| Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy | Q41695164 | ||
| The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. | Q41744993 | ||
| Diet-induced obesity and kidney disease - In search of a susceptible mouse model | Q42062261 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal fibrosis | Q18553516 |
| P304 | page(s) | e0166272 | |
| P577 | publication date | 2016-11-09 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage | |
| P478 | volume | 11 |
| Q33754895 | Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment |
| Q90169765 | Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs |
| Q89429779 | Galectin-1 is a new fibrosis protein in type 1 and type 2 diabetes |
| Q55040652 | Hypoxia-inducible factor-1α regulates epithelial-to-mesenchymal transition in paraquat-induced pulmonary fibrosis by activating lysyl oxidase. |
| Q60050018 | IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI |
| Q47649685 | Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. |
| Q64923813 | Interaction between galectin-3 and cystinosin uncovers a pathogenic role of inflammation in kidney involvement of cystinosis. |
| Q91877907 | Letter to the Editor: Not all modified citrus pectins are the same: size does matter |
| Q40060474 | Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease |
| Q47127873 | Synergistic Antioxidant and Anti-Inflammatory Effects between Modified Citrus Pectin and Honokiol |
Search more.